New drug aims to shrink tumors before kidney cancer surgery
NCT ID NCT07226544
Summary
This study is testing if a new immunotherapy drug called ivonescimab can shrink tumors in patients with high-risk kidney cancer that hasn't spread. The drug is given by IV for about 3 months before the patient's standard surgery to remove the kidney. Researchers want to see if this pre-surgery treatment makes the cancer easier to remove and reduces the chance of it coming back.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IV RENAL CELL CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.